Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06244186
Other study ID # CMUH110-REC2-070
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 10, 2021
Est. completion date November 3, 2023

Study information

Verified date February 2024
Source China Medical University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the improvement in weight, body fat, and BMI after adding probiotics as a once-daily therapy for 84 days in overweight individuals.


Description:

The study product contains Lactobacillus delbrueckii subsp. Bulgaricus at a concentration of 1x10^8 CFU in each 100 mg. The objective of this study is to evaluate the benefits of probiotics as an add-on therapy in overweight individuals by assessing the improvements in weight, body fat, and BMI after adding probiotics as a once-daily therapy for 84 days. A randomized, two-regimen, placebo-controlled, parallel design is employed in this study, where each subject will receive either probiotics or a placebo. The add-on study product will be administered once daily for 84 days. The benefits will be assessed at baseline and subsequently on study days 28, 56, and 84, focusing on parameters such as weight, body fat, and BMI.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date November 3, 2023
Est. primary completion date November 1, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Age = 20 years old - Overweight (BMI = 23) or body fat percentage = 25% for males and = 30% for females - Having any of the following risk factors: Atherosclerotic cardiovascular disease, type 2 diabetes, age = 45 years for males, = 55 years for females or postmenopausal, hypertension, dyslipidemia (total cholesterol > 200 mg/dL or low-density lipoprotein cholesterol > 130 mg/dL or triglycerides > 130 mg/dL), high-density lipoprotein cholesterol < 40 mg/dL - If routinely taking medication for lowering blood glucose, blood pressure, or lipid levels, there should not be significant dosage changes within the past three months - Being willing to participate after receiving an explanation from the physician, completing the trial plan, and signing the consent form Exclusion Criteria: - History of diabetic ketoacidosis - Medical records indicating the occurrence of cerebrovascular disease, acute myocardial infarction, coronary artery bypass surgery, placement of coronary artery stents, or peripheral vascular disease within the last 6 months - Occurrence of acute infectious diseases within the last month and antibiotic use for > 7 days - Short-term use of steroids, NSAIDs, immunosuppressive drugs, interferons, immunomodulators, or any changes in the dose of long-term medications within the last month - Use of any weight-loss drugs in the last three months (including Orlistat, Lorcaserin, and liraglutide) - History of any cancer or undergoing cancer treatment in the past 5 years - Abnormal liver function (GOT or GPT greater than 3 times the normal upper limit) or liver cirrhosis - Impaired kidney function (eGFR < 30 mL/min/1.73 m2) - History of alcohol abuse - Participation in any other interventional clinical research within the last month - Pregnant and breastfeeding women - History of allergy to the investigational product - Participants deemed unsuitable for inclusion by the principal investigator

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotics
Probiotics contains a probiotic known as Lactobacillus delbrueckii subsp. Bulgaricus, a key bacterium utilized in the production of yogurt, cheeses, and various naturally fermented products. Studies suggest that the metabolites of Lactobacillus bulgaricus can enhance immunity and digestion, reduce the risk of infection, and lower blood cholesterol levels. The composition of probiotics has been developed by TCI CO., Ltd.
Placebo
Placebo is provided by TCI CO., Ltd.

Locations

Country Name City State
Taiwan China Medical University Hospital Taichung

Sponsors (2)

Lead Sponsor Collaborator
China Medical University Hospital TCI Co., Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Body weight Comparing the changes between Day 0 and Day 84 84 days
Primary Body fat Comparing the changes between Day 0 and Day 84 84 days
Primary BMI Comparing the changes between Day 0 and Day 84 84 days
Secondary ALT and AST (U/L) in Blood composition Comparing the changes in ALT and AST (alanine aminotransferase, aspartate aminotransferase) in the blood between Day 0 and Day 84 84 days
Secondary CRE, BUN and GLU-AC (mg/dL) in Blood composition Comparing the changes in CRE, BUN, and GLU-AC (creatinine, blood urea nitrogen, fasting blood glucose) in the blood between Day 0 and Day 84 84 days
Secondary Changes in glycated hemoglobin Comparing the changes in hemoglobin A1c between Day 0 and Day 84. 84 days
Secondary Changes in CHOL, TG, HDL and LDL-C (mg/dL) in Blood composition Comparing the changes in CHOL, TG, HDL, and LDL-C (cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol) between Day 0 and Day 84. 84 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Completed NCT04611477 - Effect of Synbiotic 365 on Body Composition in Overweight and Obese Individuals N/A
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A